AdvertisementSTOCKHOLM, Jan. 24, 2024 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, today January 24, 2024. CEO Jens Lindberg will present the company and updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) at 15.20 CET. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. The following files are available for download:https://mb.cision.com/Main/652/3914524/2559339.pdf Press release (PDF)View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-redeye-fight-cancer-day-302042942.htmlSOURCE MedivirDisclaimer: The above press release comes to you under an arrangement with PR Newswire.

Source: The Bubble January 24, 2024 20:00 UTC